Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy

The adaptive immune system is modulated by an important subset of CD4(+) T lymphocytes called Treg cells that function in maintaining immune homeostasis by preventing excessive immune activation. Both deficiency and overactivation of Treg cell function can result in disease pathology. While loss of Treg function can lead to autoimmunity, an overabundance of Treg activity can promote tumorigenesis. Blocking and/or depleting Tregs has emerged as a viable strategy to enhance antitumor immunity. A major limitation underlying the limited efficacy observed with Treg therapies in the clinic is lack of selective targeting, often attributed to concurrent depletion of antitumor effector T-cell populations. Novel approaches to improve the specificity of Treg targeting in the context of cancer include the use of T-cell receptor mimic antibodies, bispecific antibodies, and near-infrared photoimmunotherapy. Next-generation technology platforms and transcriptomic/computational-based screening methods have been recently developed to identify preferential Treg targets. Herein, we highlight key advancements and challenges pertaining to the development of novel Treg targeting cancer therapeutics and discuss ongoing clinical trials evaluating next-generation Treg therapies for solid tumors.

Automated summary

Treg cells play a crucial role in maintaining immune homeostasis, and targeting them can enhance antitumor immunity, although the efficacy of current Treg therapies in clinical settings is limited due to lack of specificity. Novel approaches, such as T-cell receptor mimic antibodies and near-infrared photoimmunotherapy, aim to address this limitation in the context of cancer.